Strategic License and Research and Collaboration Agreements - Additional Information (Details) £ in Millions	1 Months Ended				3 Months Ended		9 Months Ended
	May 31, 2024 USD ($)	Oct. 31, 2023 USD ($)	Feb. 28, 2022 USD ($)	Nov. 30, 2015 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 GBP (£)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Prepaid research and development costs					$ 6,088,000		$ 6,088,000			$ 24,297,000
Research and development expenses					60,630,000	$ 41,601,000	155,015,000		$ 103,855,000
2015 TSRI License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones achieved					0		0
Milestone Payments		$ 300,000
Accrued Royalties					0		$ 0
2015 TSRI License Agreement | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development and regulatory milestone payments				$ 1,500,000
Commercial milestone payments				$ 3,500,000
Amgen Research and Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration agreement termination description							The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 2024.	The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 2024.
Research and collaboration agreement quarterly payments for first two year							$ 50,000,000
Prepaid research and development costs										$ 6,300,000
Research and development expenses					12,500,000	$ 8,100,000	12,500,000		$ 24,400,000
Amgen Research and Collaboration Agreement | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and collaboration agreement quarterly payments for third year							$ 12,500,000
First Vanderbilt Research Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and collaboration agreement quarterly payments			$ 1,700,000
Research agreement expiry date							2023-09	2023-09
Second Vanderbilt Research Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research agreement expiry date							2024-11	2024-11
Second Vanderbilt Research Agreement | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and collaboration agreement payments	$ 500,000
Parkinson's Research Ventures Funding Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expenses					$ 600,000		$ 600,000
Funds received upon execution of agreement | £								£ 0.9
Payments for execution of agreement							$ 1,100,000
Fund eligible to receive upon completion of certain development milestone | £								1.2
Maximum repayment amount agreed to pay. | £								8.4
Parkinson's Research Ventures Funding Agreement | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Funds provided for preclinical research and development activities | £								£ 2.1